Interaction of CD137 with its ligand (CD137L, also known as TNFSF9 or 4-1BBL) on activated antigen-presenting cells (APCs) could lead to bidirectional activation that promotes immunity against cancer [3]. Here, TNFSF9 is linked to cancer.